News | August 31, 2022
Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
It is high time that India assumed a leadership role in healthcare.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Therapy recently approved in Canada under the brand name KORSUVA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Subscribe To Our Newsletter & Stay Updated
